Abstract: The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.
Type:
Grant
Filed:
March 14, 2018
Date of Patent:
February 25, 2020
Assignee:
DS Biopharma Limited
Inventors:
Mehar Manku, John Climax, David Coughlan
Abstract: The present disclosure provides pharmaceutically acceptable stable salt forms of 15-lipoxygenase products, such as 15-HETrE lysine salt, compositions comprising same and methods of making and using same.
Type:
Grant
Filed:
December 1, 2017
Date of Patent:
January 28, 2020
Assignee:
DS Biopharma Limited
Inventors:
Mehar Manku, David Coughlan, Bill Downes
Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.
Type:
Grant
Filed:
February 19, 2019
Date of Patent:
January 21, 2020
Assignee:
DS Biopharma Limited
Inventors:
Mehar Manku, John Climax, David Coughlan, James Dunne
Abstract: The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, for use in treating various skin disorders.
Type:
Grant
Filed:
December 28, 2017
Date of Patent:
June 25, 2019
Assignee:
DS Biopharma Limited
Inventors:
Adam Kelliher, Angus Morrison, Phil Knowles
Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.
Type:
Grant
Filed:
July 27, 2017
Date of Patent:
October 23, 2018
Assignee:
DS BIOPHARMA LIMITED
Inventors:
Mehar Manku, John Climax, David Coughlan, James Dunne
Abstract: The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.
Type:
Grant
Filed:
May 12, 2016
Date of Patent:
August 14, 2018
Assignee:
DS BIOPHARMA LIMITED
Inventors:
Mehar Manku, John Climax, David Coughlan
Abstract: The present disclosure provides pharmaceutically acceptable stable salt forms of 15-lipoxygenase products, such as 15-HETrE lysine salt, compositions comprising same and methods of making and using same.
Type:
Grant
Filed:
November 17, 2014
Date of Patent:
July 10, 2018
Assignee:
DS BIOPHARMA LIMITED
Inventors:
Mehar Manku, David Coughlan, Bill Downes
Abstract: The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, for use in treating various skin disorders.
Type:
Grant
Filed:
July 18, 2016
Date of Patent:
February 13, 2018
Assignee:
DS BIOPHARMA LIMITED
Inventors:
Adam Kelliher, Angus Morrison, Phil Knowles
Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, and/or 15-HETrE, used singly or in combination for the prevention and/or treatment of effects associated with UV radiation such as erythema.
Type:
Grant
Filed:
December 9, 2014
Date of Patent:
January 2, 2018
Assignee:
DS BIOPHARMA LIMITED
Inventors:
Mehar Manku, John Climax, David Coughlan